Information, not a decision

Kidney cancer: tumour board sheet

Dated public registry data. It contains no treatment recommendation. 12 Nov 2026

Open trials (527)

NCT07928167	Phase 2	Lenvatinib And Stereotactic radiothErapy With pembRolizumab in Metastatic Kidney Cancer Patients	Recruiting
NCT07292168	Phase 1/2	A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1	Recruiting
NCT07489495	Phase 3	A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)	Recruiting
NCT00102544	No phase	Use of Tracking Devices to Locate Abnormalities During Invasive Procedures	By invitation only
NCT05155033	Phase 2	Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma	Recruiting
NCT07187778	Phase 2	Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)	Recruiting
NCT07925333	Phase 2	Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer	Not yet recruiting
NCT07922915	Phase 2	Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell Carcinoma	Not yet recruiting
NCT04198766	Phase 1/2	Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)	Recruiting
NCT07922928	Phase 2	Toripalimab and Lenvatinib With or Without SBRT Before Surgery for Non-Clear Cell Kidney Cancer	Not yet recruiting
NCT07087158	Phase 2	A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma	Recruiting
NCT03866382	Phase 2	Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors	Recruiting

515 more in the doctor's list on the site.

Phase 3 trials that ended in the last 90 days

NCT05522231

28 Aug 2026

Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)

Completed

Guidelines

Links only: read the guideline itself.

Made from the public data of Frontlight Research. Source: ClinicalTrials.gov. 12 Nov 2026

https://frontlightresearch.com/en/doctor/kidney-cancer/tumor-board